IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

168

Participants

Timeline

Start Date

September 6, 2022

Primary Completion Date

December 24, 2026

Study Completion Date

December 24, 2026

Conditions

Ovarian Cancer Recurrent

Interventions

DRUG

IN10018

100mg QD orally (PO)

DRUG

Placebo of IN10018

100mg QD orally (PO)

DRUG

Pegylated Liposomal Doxorubicin

40 mg/m2 once every 4 weeks (Q4W) intravenously (IV)

Trial Locations (1)

RECRUITING

Cancer Hospital Chinese Academy of Medical Science and Peking Union Medical College, Beijing

All Listed Sponsors

lead

InxMed (Shanghai) Co., Ltd.

INDUSTRY